The Simcyp Population Based Simulator: Architecture, Implementation, and Quality Assurance

Developing a user-friendly platform that can handle a vast number of complex physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) models both for conventional small molecules and larger biologic drugs is a substantial challenge. Over the last decade the Simcyp Population Based Simulator has gained popularity in major pharmaceutical companies (70% of top 40 - in term of R&D spending). Under the Simcyp Consortium guidance, it has evolved from a simple drug-drug interaction tool to a sophisticated and comprehensive Model Based Drug Development (MBDD) platform that covers a broad range of applications spanning from early drug discovery to late drug development. This article provides an update on the latest architectural and implementation developments within the Simulator. Interconnection between peripheral modules, the dynamic model building process and compound and population data handling are all described. The Simcyp Data Management (SDM) system, which contains the system and drug databases, can help with implementing quality standards by seamless integration and tracking of any changes. This also helps with internal approval procedures, validation and auto-testing of the new implemented models and algorithms, an area of high interest to regulatory bodies.

• Publication year

  2013

• Venue

  In Silico Pharmacology

• Publication date

  2013-06-03

• Fields of study

  Medicine, Computer Science, Engineering

• Identifiers
  DOI 10.1186/2193-9616-1-9PMID 25505654PMCID 4230310
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Agile Software Development: Principles, Patterns, and Practices

  2014cited by this paper
• Physiologically Based Pharmacokinetics Joined With In Vitro–In Vivo Extrapolation of ADME: A Marriage Under the Arch of Systems Pharmacology

  2012cited by this paper
• Scrum: a Breathtakingly Brief and Agile Introduction

  2012cited by this paper
• Evaluation of Exposure Change of Nonrenally Eliminated Drugs in Patients With Chronic Kidney Disease Using Physiologically Based Pharmacokinetic Modeling and Simulation

  2012cited by this paper
• Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?

  2012cited by this paper
• Physiologically-based pharmacokinetics in drug development and regulatory science.

  2011cited by this paper
• Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review

  2011cited by this paper
• The Simcyp population-based ADME simulator.

  2009influential reference
• A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates.

  2009influential reference
• The Statistical Analysis of Failure Time Data

  2003cited by this paper
• Iterative and incremental developments. a brief history

  2003cited by this paper
• The Statistical Analysis of Failure Time Data: Kalbfleisch/The Statistical

  2002cited by this paper
• Generalized Linear Models

  2002cited by this paper
• General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition

  2001cited by this paper
• Drug treatment effects on disease progression.

  2001cited by this paper
• Agile Software Development: Software Through People

  2001cited by this paper
• Commentary: a plausible model.

  1999cited by this paper
• A MODIFICATION OF RECEPTOR THEORY

  1997cited by this paper
• Description and use of LSODE, the Livermore Solver for Ordinary Differential Equations

  1993cited by this paper
• Comparison of four basic models of indirect pharmacodynamic responses

  1993cited by this paper
• Generalized Linear Models

  1992cited by this paper
• On the Application of R -Curves and Maximum Load Toughness to Structures

  1988cited by this paper
• Genetic Algorithms in Search Optimization and Machine Learning

  1988cited by this paper
• An operational model of pharmacological agonism: the effect of E/[A] curve shape on agonist dissociation constant estimation

  1985cited by this paper
• Automatic Selection of Methods for Solving Stiff and Nonstiff Systems of Ordinary Differential Equations

  1983cited by this paper
• The Statistical Analysis of Failure Time Data

  1980cited by this paper
• Maximum likelihood from incomplete data via the EM - algorithm plus discussions on the paper

  1977cited by this paper
• Numerical Initial Value Problems in Ordinary Differential Equations

  1972cited by this paper
• On the application of "a plausible model" of allosteric proteins to the receptor for acetylcholine.

  1967cited by this paper
• A Simplex Method for Function Minimization

  1965cited by this paper
• `` Direct Search'' Solution of Numerical and Statistical Problems

  1961cited by this paper
• STUDIES ON THE DIFFUSION EFFECT UPON IONIC DISTRIBUTION

  1937cited by this paper

• Modular dynamics paradigm in biosystems multilevel modeling: Software design and PBPK/PD validation

  2025cites this paper
• AI and Machine Learning Models for Identifying Generic and Patentable Medicines: A Techno-Legal Approach

  2025cites this paper
• Concentration-dependent blood binding: assessing implications through physiologically based Pharmacokinetic modeling of tacrolimus as a case example

  2025cites this paper
• The Impact of Using Measured In Vitro Data to Develop Physiologically Based Pharmacokinetic Models of Dermal Absorption: An IVIVE Case Study

  2025cites this paper
• A Combined Modeling Approach to Predict the Effect of Gastric Emptying Delay on the Pharmacokinetics of Small Molecules

  2025cites this paper
• Applying New Approach Methods for Toxicokinetics for Chemical Risk Assessment.

  2025cites this paper
• Determination of the latent geometry of atorvastatin pharmacokinetics by transfer entropy to identify bottlenecks

  2025cites this paper
• Bioequivalence risk assessment of oral formulations containing racemic ibuprofen through a chiral physiologically based pharmacokinetic model of ibuprofen enantiomers.

  2024cites this paper
• An in vitro-in silico workflow for predicting renal clearance of PFAS.

  2024cites this paper
• Interspecies Brain PBPK Modeling Platform to Predict Passive Transport through the Blood–Brain Barrier and Assess Target Site Disposition

  2024cites this paper
• Integration of Biorelevant Pediatric Dissolution Methodology into PBPK Modeling to Predict In Vivo Performance and Bioequivalence of Generic Drugs in Pediatric Populations: a Carbamazepine Case Study

  2023cites this paper
• The African Liver Tissue Biorepository Consortium: Capacitating Population-Appropriate Drug Metabolism, Pharmacokinetics, and Pharmacogenetics Research in Drug Discovery and Development

  2023cites this paper
• Can Mechanistic Static Models for Drug-Drug Interactions Support Regulatory Filing for Study Waivers and Label Recommendations?

  2023influential citation
• A dynamic model of the intestinal epithelium integrates multiple sources of preclinical data and enables clinical translation of drug‐induced toxicity

  2023influential citation
• Advancing Algorithmic Drug Product Development: Recommendations for Machine Learning Approaches in Drug Formulation.

  2023cites this paper
• An Integrative Approach to Elucidate Mechanisms Underlying the Pharmacokinetic Goldenseal-Midazolam Interaction: Application of In Vitro Assays and Physiologically Based Pharmacokinetic Models to Understand Clinical Observations

  2023cites this paper
• Application of physiologically based pharmacokinetic modeling to understand real‐world outcomes in patients receiving imatinib for chronic myeloid leukemia

  2023cites this paper
• Development of Simulation and Visualization System of Aircraft Assembly Process Technology Based on DELMIA Software

  2023cites this paper
• A Population-Based Human In Vitro Approach to Quantify Inter-Individual Variability in Responses to Chemical Mixtures

  2022cites this paper
• In-Depth Analysis of Physiologically Based Pharmacokinetic (PBPK) Modeling Utilization in Different Application Fields Using Text Mining Tools

  2022cites this paper
• Physiologically based modelling of dermal absorption and kinetics of consumer-relevant chemicals: A case study with exposure to bisphenol A from thermal paper.

  2022cites this paper
• Physiologically Based Pharmacokinetic Modeling of Nanoparticle Biodistribution: A Review of Existing Models, Simulation Software, and Data Analysis Tools

  2022cites this paper
• Case Study on Certara’s Simcyp PBPK Simulator to Eliminate Lengthy Clinical Trails

  2022cites this paper
• The application of virtual therapeutic drug monitoring to assess the pharmacokinetics of imatinib in a Chinese Cancer population group.

  2022cites this paper
• SimRFlow: An R-based workflow for automated high-throughput PBPK simulation with the Simcyp® simulator

  2022cites this paper
• A systems approach reveals species differences in hepatic stress response capacity

  2022cites this paper
• Rats exhibit higher hepatic stress response pathway capacities compared with mice and humans

  2022cites this paper
• Population PBPK modeling using parametric and nonparametric methods of the Simcyp Simulator, and Bayesian samplers

  2022cites this paper
• Nanomedicine Ex Machina: Between Model-Informed Development and Artificial Intelligence

  2022cites this paper
• Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinib

  2022cites this paper
• Use of Modeling and Simulation to Predict the Influence of Triazole Antifungal Agents on the Pharmacokinetics of Crizotinib

  2022cites this paper
• Artemisinin Cocrystals for Bioavailability Enhancement: Part 2. In-vivo Bioavailability and PBPK Modelling

  2021cites this paper
• Physiologically‐Based Pharmacokinetic Modeling of Remdesivir and Its Metabolites to Support Dose Selection for the Treatment of Pediatric Patients With COVID‐19

  2021cites this paper
• Teicoplanin physiologically based pharmacokinetic modeling offers a quantitative assessment of a theoretical influence of serum albumin and renal function on its disposition

  2021cites this paper
• Artemisinin Cocrystals for Bioavailability Enhancement. Part 2: In Vivo Bioavailability and Physiologically Based Pharmacokinetic Modeling.

  2021cites this paper
• Physiologically Based Pharmacokinetic (PBPK) Modeling: Software

  2021cites this paper
• Physiologically Based Models: Techniques and Applications to Drug Delivery

  2021cites this paper
• Physiologically‐based pharmacokinetic model predictions of inter‐ethnic differences in imatinib pharmacokinetics and dosing regimens

  2021cites this paper
• Application of Model Informed Precision Dosing to Address the Impact of Pregnancy Stage and CYP2D6 Phenotype on Foetal Morphine Exposure

  2021cites this paper
• Physiologically Based Pharmacokinetic Models Are Effective Support for Pediatric Drug Development

  2021cites this paper
• A hybrid modeling approach for assessing mechanistic models of small molecule partitioning in vivo using a machine learning-integrated modeling platform

  2021cites this paper
• Current Evidence, Challenges, and Opportunities of Physiologically Based Pharmacokinetic Models of Atorvastatin for Decision Making

  2021cites this paper
• Feasibility of physiologically based pharmacokinetic simulations for assessing pediatric patients after accidental drug ingestion: A case study of a 1.4-year-old girl who ingested alprazolam.

  2021cites this paper
• Insights into Praziquantel metabolism and potential enantiomeric CYP-mediated drug-drug interaction

  2020cites this paper
• Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in Paediatrics

  2020cites this paper
• Physiologically Based Pharmacokinetic Modelling of Glycopyrronium in Patients with Renal Impairment.

  2020cites this paper
• Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically‐based pharmacokinetic modelling approach

  2020cites this paper
• PBPK modeling of impact of nonalcoholic fatty liver disease on toxicokinetics of perchloroethylene in mice.

  2020cites this paper
• Physiologically-Based Pharmacokinetic Predictions of the Effect of Curcumin on Metabolism of Imatinib and Bosutinib: In Vitro and In Vivo Disconnect

  2020cites this paper
• Physiologically based pharmacokinetic models to support modernized chemical safety assessment

  2020cites this paper
• Ribociclib Drug-Drug Interactions - Clinical Evaluations and PBPK Modeling to Guide Drug Labeling.

  2020cites this paper
• Chemical concentrations in cell culture compartments (C5) - free concentrations.

  2020cites this paper
• Examination of Physiologically‐Based Pharmacokinetic Models of Rosuvastatin

  2020cites this paper
• Development of a Physiologically Based Pharmacokinetic Model for Prediction of Ethanol Concentration-Time Profile in Different Organs.

  2020cites this paper
• Physiologically‐Based Pharmacokinetic Modeling of the Drug–Drug Interaction of the UGT Substrate Ertugliflozin Following Co‐Administration with the UGT Inhibitor Mefenamic Acid

  2020influential citation
• Physiological‐based pharmacokinetic modeling trends in pharmaceutical drug development over the last 20‐years; in‐depth analysis of applications, organizations, and platforms

  2020cites this paper
• Prediction of Human Nonlinear Pharmacokinetics of a New Bcl-2 Inhibitor Using PBPK Modeling and Interspecies Extrapolation Strategy

  2019cites this paper
• Physiologically‐Based Pharmacokinetic Modeling for the Prediction of CYP2D6‐Mediated Gene–Drug–Drug Interactions

  2019cites this paper
• Accounting for inter-correlation between enzyme abundance: a simulation study to assess implications on global sensitivity analysis within physiologically-based pharmacokinetics

  2019cites this paper
• Development of a physiologically-based pharmacokinetic pediatric brain model for prediction of cerebrospinal fluid drug concentrations and the influence of meningitis

  2019cites this paper
• Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John’s Wort

  2019cites this paper
• The Pharmacokinetic Prediction of Cyclosporin A after Coadministration with Wuzhi Capsule

  2019cites this paper
• Impact of reduced P‐glycoprotein function on digoxin concentrations in patients with dementia

  2019cites this paper
• Bottom-up physiologically-based biokinetic modelling as an alternative to animal testing.

  2019cites this paper
• Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment

  2019cites this paper
• Physiologically-based pharmacokinetic modeling for the prediction of CYP 2 D 6-mediated gene-drug-drug interactions

  2019cites this paper
• Caracterización in silico de la farmacocinética de clozapina en distintas poblaciones de pacientes.

  2019cites this paper
• Tiered approaches for screening and prioritizing chemicals through integration of pharmacokinetics and exposure information with in vitro dose-response data

  2019cites this paper
• A Strategy to Refine the Phenotyping Approach and Its Implementation to Predict Drug Clearance: A Physiologically Based Pharmacokinetic Simulation Study

  2018cites this paper
• An Investigation into the Prediction of the Plasma Concentration-Time Profile and Its Interindividual Variability for a Range of Flavin-Containing Monooxygenase Substrates Using a Physiologically Based Pharmacokinetic Modeling Approach

  2018cites this paper
• Development of a Physiologically Based Pharmacokinetic Model of Ethionamide in the Pediatric Population by Integrating Flavin‐Containing Monooxygenase 3 Maturational Changes Over Time

  2018cites this paper
• Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Drug Exposure

  2018cites this paper
• In silico (computed) modelling of doses and dosing regimens associated with morphine levels above international legal driving limits

  2018cites this paper
• Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective

  2018cites this paper
• Application of Physiologically Based Pharmacokinetic (PBPK) Modeling Within a Bayesian Framework to Identify Poor Metabolizers of Efavirenz (PM), Using a Test Dose of Efavirenz

  2018cites this paper
• Using a Vancomycin PBPK Model in Special Populations to Elucidate Case‐Based Clinical PK Observations

  2018cites this paper
• Towards Further Verification of Physiologically-Based Kidney Models: Predictability of the Effects of Urine-Flow and Urine-pH on Renal Clearance

  2018cites this paper
• A Novel PBPK Modeling Approach to Assess Cytochrome P450 Mediated Drug‐Drug Interaction Potential of the Cytotoxic Prodrug Evofosfamide

  2018cites this paper
• Physiologically-based pharmacokinetic modeling for mirabegron: a multi-elimination pathway mediated by cytochrome P450 3A4, uridine 5'-diphosphate-glucuronosyltransferase 2B7, and butyrylcholinesterase

  2018cites this paper
• Physiologically based pharmacokinetic modelling to guide drug delivery in older people

  2018cites this paper
• Modèles statistiques pour l'extrapolation de l'information adulte à l'enfant dans les essais cliniques

  2017cites this paper
• Mechanistic Physiologically Based Pharmacokinetic (PBPK) Model of the Heart Accounting for Inter-Individual Variability: Development and Performance Verification.

  2017cites this paper
• Real Patient and its Virtual Twin: Application of Quantitative Systems Toxicology Modelling in the Cardiac Safety Assessment of Citalopram

  2017cites this paper
• PharmML in Action: an Interoperable Language for Modeling and Simulation

  2017cites this paper
• Discovering new drug-drug interactions using data science: Applications to drug-induced Long QT Syndrome

  2017cites this paper
• Quantitative Simulation on Concentration-Time Profiles of Oxycodone Co-administration with Diazepam

  2017cites this paper
• A four-compartment PBPK heart model accounting for cardiac metabolism - model development and application

  2017cites this paper
• In vitro metabolism of the anti-inflammatory clerodane diterpenoid polyandric acid A and its hydrolysis product by human liver microsomes and recombinant cytochrome P450 and UDP-glucuronosyltransferase enzymes

  2017influential citation
• Prediction of liver volume – a population‐based approach to meta‐analysis of paediatric, adult and geriatric populations – an update

  2017cites this paper
• Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations

  2017cites this paper
• The effect of increasing amitriptyline doses on cardiomyocytes’ electrophysiology – simulation study

  2016cites this paper
• A Tutorial on Pharmacodynamic Scripting Facility in Simcyp

  2016cites this paper
• Addressing Early Life Sensitivity Using Physiologically Based Pharmacokinetic Modeling and In Vitro to In Vivo Extrapolation

  2016cites this paper
• Assessment of DCE–MRI parameters for brain tumors through implementation of physiologically–based pharmacokinetic model approaches for Gd-DOTA

  2016cites this paper
• IN SILICO MODELING OF METABOLITE KINETICS

  2016cites this paper
• Physiological scaling factors and mechanistic models for prediction of renal clearance from in vitro data

  2016cites this paper
• Critical Path to Tuberculosis Drug Regimens: Global collaboration to accelerate development of novel drug regimens and rapid drug susceptibility tests for tuberculosis

  2016cites this paper
• Antibody–Drug Conjugates: Clinical Strategies and Applications

  2016cites this paper
• Development of quantitative systems pharmacology and toxicology models within consortia: experiences and lessons learned through DILIsym development

  2016cites this paper
• Developing a Physiologically-Based Pharmacokinetic Model Knowledgebase in Support of Provisional Model Construction

  2016cites this paper